SITC Cancer Immunotherapy Guidelines - Non-Small Cell Lung Cancer (NSCLC) Recorded Webinar

View Recorded Webinar

 

Learn more about immunotherapy treatment standards for non-small cell lung cancer from the SITC Cancer Immunotherapy Guidelines- Non-Small Cell Lung Cancer (NSCLC) on-demand webinar. The on-demand webinar discusses treatment standards described in the SITC Cancer Immunotherapy Guidelines – Non-Small Cell Lung Cancer manuscript. 

The webinar faculty presented and discussed:

  • The role of immunotherapy for the treatment of NSCLC
  • The role of patient biomarker testing for prognostic use as well as optimizing treatment selection
  • Unique disease cases that may require adaption of immunotherapy utilization
  • How best to manage immune-related adverse events

 

Webinar Faculty

Roy S. Herbst, MD, PhD - Yale Cancer Center

Julie R. Brahmer, MD - Sidney Kimmel Comprehensive Cancer Center

Patrick Forde, MD - Johns Hopkins University

Scott N. Gettinger, MD - Yale Cancer Center

 

Webinar Date

September 13, 2018

 

Please note that the recorded webinar is not available for continuing education credits.

Course Objectives
Upon completion of this activity, participants will be able to:
  • Describe the current guidelines for implementing cancer immunotherapy into practice based on the latest approvals and technologies available in the field.
  • Identify how to incorporate cancer immunotherapy into clinical practice according to the SITC guidelines.
  • Implement cancer immunotherapy treatments according to the SITC cancer immunotherapy guidelines.
SITC Cancer Immunotherapy Guidelines - Non-small Cell Lung Cancer (NSCLC) Recorded Webinar

On September 13, 2018, leading experts in cancer immunotherapy presented an overview of the recently updated SITC Cancer Immunotherapy Guidelines - Non-small Cell Lung Cancer (NSCLC) at a live webinar.
 

The webinar faculty presented and discussed:

  • The role of immunotherapy for the treatment of NSCLC
  • The role of patient biomarker testing for prognostic use as well as optimizing treatment selection
  • Unique disease cases that may require adaption of immunotherapy utilization
  • How best to manage immune-related adverse events

 

A dedicated question-and-answer session during the webinar will provide an opportunity for attendees to converse with the faculty and ask questions about the guideline recommendations.

Individual topic purchase: Selected